Fennec Pharmaceuticals (FENC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $13.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors including Fennec Pharmaceuticals’ strong financial performance and strategic market expansion. The company reported a net revenue of $8.8 million for 1Q25, which was in line with expectations, and a net loss significantly lower than anticipated, driven by reduced operating expenses. This financial performance indicates effective cost management and commercial traction for their product, PEDMARK.
Additionally, Fennec is making significant strides in expanding its market presence, particularly with the European rollout of PEDMARQSI, its sodium thiosulfate product. The acceptance of PEDMARQSI by the Scottish Medicines Consortium and its commercial launches in Germany, England, and Wales highlight the company’s commitment to broadening access to its products. These developments, coupled with the potential for further market penetration in regions like China and Japan, support the positive outlook for Fennec Pharmaceuticals, justifying the Buy rating and a 12-month price target of $13.
In another report released on May 15, Maxim Group also maintained a Buy rating on the stock with a $15.00 price target.
Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is neutral on the stock.